Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-invasive Cancer Diagnostics Market

4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Non-invasive Cancer Diagnostics Market Value Analysis and Forecast, 2017–2031

5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Urine Test
6.3.2. Imaging Test
6.3.2.1. Computerized Tomography
6.3.2.2. Magnetic Resonance Imaging
6.3.2.3. Nuclear Medicine Scans
6.3.2.4. X-ray/Mammography
6.3.2.5. Ultrasound
6.3.3. Spectroscopy
6.4. Market Attractiveness Analysis, by Test Type

7. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2017–2031
7.3.1. Breast Cancer
7.3.2. Lung Cancer
7.3.3. Blood Cancer
7.3.4. Ovarian Cancer
7.3.5. Colorectal Cancer
7.3.6. Others
7.4. Market Attractiveness Analysis, by Cancer Type

8. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Care
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user

9. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Non-invasive Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Urine Test
10.2.2. Imaging Test
10.2.2.1. Computerized Tomography
10.2.2.2. Magnetic Resonance Imaging
10.2.2.3. Nuclear Medicine Scans
10.2.2.4. X-ray/Mammography
10.2.2.5. Ultrasound
10.2.3. Spectroscopy
10.3. Market Value Forecast, by Cancer Type, 2017–2031
10.3.1. Breast Cancer
10.3.2. Lung Cancer
10.3.3. Blood Cancer
10.3.4. Ovarian Cancer
10.3.5. Colorectal Cancer
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals & Clinics
10.4.2. Ambulatory Care
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Cancer Type
10.6.3. By End-user
10.6.4. By Country

11. Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Urine Test
11.2.2. Imaging Test
11.2.2.1. Computerized Tomography
11.2.2.2. Magnetic Resonance Imaging
11.2.2.3. Nuclear Medicine Scans
11.2.2.4. X-ray/Mammography
11.2.2.5. Ultrasound
11.2.3. Spectroscopy
11.3. Market Value Forecast, by Cancer Type, 2017–2031
11.3.1. Breast Cancer
11.3.2. Lung Cancer
11.3.3. Blood Cancer
11.3.4. Ovarian Cancer
11.3.5. Colorectal Cancer
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals & Clinics
11.4.2. Ambulatory Care
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region

12. Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Urine Test
12.2.2. Imaging Test
12.2.2.1. Computerized Tomography
12.2.2.2. Magnetic Resonance Imaging
12.2.2.3. Nuclear Medicine Scans
12.2.2.4. X-ray/Mammography
12.2.2.5. Ultrasound
12.2.3. Spectroscopy
12.3. Market Value Forecast, by Cancer Type, 2017–2031
12.3.1. Breast Cancer
12.3.2. Lung Cancer
12.3.3. Blood Cancer
12.3.4. Ovarian Cancer
12.3.5. Colorectal Cancer
12.3.6. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals & Clinics
12.4.2. Ambulatory Care
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region

13. Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Urine Test
13.2.2. Imaging Test
13.2.2.1. Computerized Tomography
13.2.2.2. Magnetic Resonance Imaging
13.2.2.3. Nuclear Medicine Scans
13.2.2.4. X-ray/Mammography
13.2.2.5. Ultrasound
13.2.3. Spectroscopy
13.3. Market Value Forecast, by Cancer Type, 2017–2031
13.3.1. Breast Cancer
13.3.2. Lung Cancer
13.3.3. Blood Cancer
13.3.4. Ovarian Cancer
13.3.5. Colorectal Cancer
13.3.6. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals & Clinics
13.4.2. Ambulatory Care
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Urine Test
14.2.2. Imaging Test
14.2.2.1. Computerized Tomography
14.2.2.2. Magnetic Resonance Imaging
14.2.2.3. Nuclear Medicine Scans
14.2.2.4. X-ray/Mammography
14.2.2.5. Ultrasound
14.2.3. Spectroscopy
14.3. Market Value Forecast, by Cancer Type, 2017–2031
14.3.1. Breast Cancer
14.3.2. Lung Cancer
14.3.3. Blood Cancer
14.3.4. Ovarian Cancer
14.3.5. Colorectal Cancer
14.3.6. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals & Clinics
14.4.2. Ambulatory Care
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. The University of Texas MD Anderson Cancer Center
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Memorial Sloan Kettering Cancer Center
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. Dana-Farber Cancer Institute
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Beverly Hills Cancer Center
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. SimonMed Imaging
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. RadNet Management, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. RAYUS Radiology (Diagnostic Services Holdings, Inc.)
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Unilabs AB
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sonic Healthcare Limited
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Dr Lal PathLabs Ltd.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis



List of Figures

List of Figures

Figure 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 03: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 04: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031

Figure 05: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 06: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 07: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 08: Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region, 2021 and 2031

Figure 09: Global Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022–2031

Figure 10: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 11: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 12: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 13: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

Figure 14: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 15: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 16: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 17: North America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country, 2021 and 2031

Figure 18: North America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022–2031

Figure 19: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 20: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 21: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 22: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type. 2021 and 2031

Figure 23: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 24: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 25: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 26: Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 27: Europe Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 28: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 29: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 30: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 31: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type 2021 and 2031

Figure 32: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 33: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 34: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 35: Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 36: Asia Pacific Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 37: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 38: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 39: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 40: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

Figure 41: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 42: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 43: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 44: Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 45: Latin America Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 46: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031

Figure 47: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type, 2021 and 2031

Figure 48: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022–2031

Figure 49: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type, 2021 and 2031

Figure 50: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2022–2031

Figure 51: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user, 2021 and 2031

Figure 52: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022–2031

Figure 53: Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031

Figure 54: Middle East & Africa Non-invasive Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 55: Global Non-invasive Cancer Diagnostics Market Share Analysis/Ranking, by Company, 2021

List of Tables

List of Tables

Table 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 02: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 03: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 06: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 07: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 10: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 11: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 14: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 15: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 18: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 19: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 22: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 23: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031